IDEAYA Biosciences (NASDAQ:IDYA) Rating Increased to Strong-Buy at BidaskClub

BidaskClub upgraded shares of IDEAYA Biosciences (NASDAQ:IDYA) from a buy rating to a strong-buy rating in a report issued on Friday morning, BidAskClub reports.

Several other research firms also recently commented on IDYA. Oppenheimer lifted their price objective on IDEAYA Biosciences from $17.00 to $25.00 and gave the stock an outperform rating in a report on Tuesday, June 16th. Zacks Investment Research downgraded IDEAYA Biosciences from a buy rating to a hold rating in a report on Tuesday, May 26th. ValuEngine upgraded IDEAYA Biosciences from a hold rating to a buy rating in a report on Tuesday, March 3rd. HC Wainwright lifted their price objective on IDEAYA Biosciences from $13.00 to $22.00 and gave the stock a buy rating in a report on Wednesday, June 17th. Finally, Roth Capital started coverage on IDEAYA Biosciences in a report on Friday, March 13th. They issued a buy rating and a $12.00 price objective on the stock. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $19.45.

NASDAQ IDYA opened at $13.25 on Friday. The stock’s 50-day simple moving average is $9.78 and its two-hundred day simple moving average is $7.47. IDEAYA Biosciences has a twelve month low of $2.95 and a twelve month high of $19.97. The company has a quick ratio of 12.18, a current ratio of 12.18 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $294.17 million and a price-to-earnings ratio of -4.48.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.02). On average, equities analysts expect that IDEAYA Biosciences will post -0.6 earnings per share for the current fiscal year.

In other news, major shareholder Bvf Partners L. P/Il acquired 98,264 shares of the business’s stock in a transaction on Friday, June 19th. The shares were acquired at an average cost of $14.39 per share, with a total value of $1,414,018.96. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Value Fund L. P. Biotechnology acquired 117,996 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $14.31 per share, for a total transaction of $1,688,522.76. Over the last three months, insiders purchased 235,992 shares of company stock worth $3,377,408 and sold 13,273 shares worth $190,783.

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its position in IDEAYA Biosciences by 234.0% during the 1st quarter. BlackRock Inc. now owns 38,218 shares of the company’s stock valued at $158,000 after acquiring an additional 26,774 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in IDEAYA Biosciences during the 4th quarter valued at approximately $151,000. Finally, Alambic Investment Management L.P. bought a new stake in IDEAYA Biosciences during the 4th quarter valued at approximately $148,000. 49.87% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Recommended Story: Gross Domestic Product (GDP)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.